Government Briefs

The new NIH regulations that determine how universities should respond to allegations of scientific misconduct (The Scientist, Sept. 4, 1989, page 1) have derailed proposed legislation in Congress. For several months Rep. John Dingell (D-Mich.) who has explored the issue in numerous hearings involving MIT biologist David Baltimore, has been on the verge of introducing legislation that would force institutions and federal agencies to be more responsive to the issue. But an aide on the House Ener

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The new NIH regulations that determine how universities should respond to allegations of scientific misconduct (The Scientist, Sept. 4, 1989, page 1) have derailed proposed legislation in Congress. For several months Rep. John Dingell (D-Mich.) who has explored the issue in numerous hearings involving MIT biologist David Baltimore, has been on the verge of introducing legislation that would force institutions and federal agencies to be more responsive to the issue. But an aide on the House Energy and Commerce Committee, which Dingell chairs, acknowledged last month that the new regulations address most of his concerns.

“They do a pretty good job of reflecting our intentions, with the exception of adequate protection for whistleblowers,” the aide noted. ‘They’ve gotten what they wanted—the chance to police themselves—and we’ll be watching to see how well they do in implementing them.”

At the same time, some of Dingell’s colleagues are worried that his efforts ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies